Normal Liver Ultrasound But High FIB-4: Why This Happens
Why a normal abdominal ultrasound and a high FIB-4 score (or elevated liver stiffness on elastography) often coexist — and what it means for next steps.
Read article →Blog
Data-led articles and buyer guides for Australian clinicians evaluating liver elastography.
21 of 21 articles
Liver Biopsy vs Elastography: A Patient's Guide
Plain-English comparison of liver biopsy and elastography for fibrosis staging — what each test involves, the risks, accuracy, and when biopsy is still required.
Read article →Resmetirom Monitoring Protocol: Elastography Timeline for Clinicians
Practical monitoring protocol for clinicians prescribing resmetirom (Rezdiffra) — baseline assessment, elastography intervals, and tracking treatment response.
Read article →MAFLD and Liver Cancer Risk: The Elastography Connection
Why metabolic fatty liver disease is now a leading cause of hepatocellular carcinoma — and how elastography fits into the surveillance pathway for at-risk patients.
Read article →How Much Does Liver Elastography Cost in Australia?
Patient-facing guide to liver elastography costs in Australia in 2026 — private pricing, Medicare rebate availability, and what affects the out-of-pocket gap.
Read article →MASLD vs NAFLD: What the Name Change Means for Patients
Why the medical community renamed NAFLD to MASLD (and NASH to MASH) — what's different, what's the same, and what it means if you've already been diagnosed.
Read article →Your FibroScan Results Explained: A Patient Guide
Plain-English guide for patients who've received FibroScan results — kPa, CAP score, IQR ratio, what the numbers mean, and what to ask your doctor next.
Read article →Mounjaro and Your Liver: What to Monitor on GLP-1 Therapy
Patient and clinician guide to liver monitoring on Mounjaro (tirzepatide) and other GLP-1 agonists — why elastography matters when weight loss meds also reduce fatty liver.
Read article →FibroScan Limitations: Australian Clinic Guide
FibroScan has documented limitations in obese patients, workflow efficiency, and operator guidance. What the evidence shows and why guided TE addresses the root causes.
Read article →Portable Liver Elastography for Regional Australia
Regional and rural Australian practices face a liver disease access gap. Guided elastography systems are changing that — here's what regional clinics need to know.
Read article →Type 2 Diabetes and MAFLD: Liver Screening Guide
Type 2 diabetes and MAFLD overlap in up to two-thirds of cases. The evidence-based screening pathway for Australian GPs managing diabetic patients with liver risk.
Read article →Hepatitis B Elastography: 2024 WHO Guidelines Explained
The 2024 WHO hepatitis B guidelines updated elastography thresholds for treatment decisions. What Australian clinicians need to know about liver stiffness in chronic HBV management.
Read article →Liver Disease Australia: 2026 Statistics and Trends
Key statistics on liver disease burden in Australia — MAFLD prevalence, liver cancer rates, screening gaps, and what the numbers mean for clinical practice.
Read article →Resmetirom for MASH: Australian Clinician Guide
Resmetirom (Rezdiffra) is the first approved MASH therapy globally. Staging, monitoring protocols, TGA status, and why elastography is central to its use in Australia.
Read article →Elastography ROI for Australian Private Clinics
How to model the return on investment for adding guided liver elastography to a private clinic or imaging centre in Australia. Scan economics, payback periods, and revenue projections.
Read article →MBS Rebate for Liver Elastography: 2025 Status Update
MSAC Application 1797 was rejected in early 2025 — no MBS rebate for liver elastography currently exists. What happened, what it means, and what comes next.
Read article →FIB-4 Indeterminate: What Comes Next in Practice?
Operational discussion of how clinics handle indeterminate FIB-4 results and when non-invasive staging pathways are considered.
Read article →GP Liver Screening: A Practical Primary-Care Pathway
How GP clinics can structure consistent liver risk workflows with clear triage, follow-up, and referral logic.
Read article →Liver Scan in Obese Patients: Australian Clinic Guide
Operational guide to non-invasive liver assessment in higher-BMI cohorts, including workflow and acquisition considerations.
Read article →FibroScan Alternatives Australia: Guided Elastography Buyer's Guide
What Australian buyers evaluate when comparing transient elastography systems: guidance, workflow, obese-patient performance, probes, and total cost of ownership.
Read article →MAFLD Screening Gap in Australian Primary Care
Why metabolic liver disease is under-detected in Australian primary care, how risk stratification is evolving, and where guided elastography fits in the pathway.
Read article →